![Vijay Karwal](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vijay Karwal
Direttore/Membro del Consiglio presso
MEGA LIFESCIENCES
Profilo
Vijay Karwal is currently an Independent Director at Mega Lifesciences Public Co. Ltd. since 2021, Managing Director at CBC Group (Singapore) Pte.
Ltd. since 2024, Independent Non-Executive Director at OneSource Specialty Pharma Ltd. starting 2025, and Chief Financial Officer at AffaMed Therapeutics (HK) Ltd. since 2021.
Formerly, Mr. Karwal was Managing Director at Nomura International (Hong Kong) Ltd. from 2018 to 2021, Chief Development Officer at Davita, Inc. (Singapore) from 2016 to 2017, and worked at ABN AMRO Bank NV (Old) from 2004 to 2011.
Education includes graduate studies at the University of Groningen.
Posizioni attive di Vijay Karwal
| Società | Posizione | Inizio |
|---|---|---|
| MEGA LIFESCIENCES | Direttore/Membro del Consiglio | 13/05/2021 |
| ONESOURCE SPECIALTY PHARMA LIMITED | Direttore/Membro del Consiglio | 27/02/2025 |
AffaMed Therapeutics (HK) Ltd.
 AffaMed Therapeutics (HK) Ltd. BiotechnologyHealth Technology Develops and commercializes ophthalmology, neurological and psychiatric products | Direttore Finanziario/CFO | 01/05/2021 |
CBC Group (Singapore) Pte. Ltd.
 CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group invests in middle market companies located in China. The firm focuses on pharmaceutical, biotechnology, medical technology and healthcare service sectors. It provides financing in the form of equity, debt and non-dilutive financing for for buyout, growth, royalty acquisitions, structured transactions and hybrid financings. It acquires controlling stake in the company. | Investitore di Private Equity | 01/05/2021 |
Precedenti posizioni note di Vijay Karwal
| Società | Posizione | Fine |
|---|---|---|
Nomura International (Hong Kong) Ltd.
 Nomura International (Hong Kong) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01/05/2021 |
Davita, Inc. (Singapore) | Corporate Officer/Principal | 01/11/2017 |
Formazione di Vijay Karwal
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
69
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
University of Groningen
 University of Groningen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nomura International (Hong Kong) Ltd.
Nomura International (Hong Kong) Ltd. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Mega Lifesciences Public Co. Ltd.
 Mega Lifesciences Public Co. Ltd. Pharmaceuticals: OtherHealth Technology Manufactures and trades health food supplements & pharmaceutical products | Health Technology |
OneSource Specialty Pharma Ltd.
 OneSource Specialty Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures GLP-1 drugs & novel biologics | Health Technology |
CBC Group (Singapore) Pte. Ltd.
CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group invests in middle market companies located in China. The firm focuses on pharmaceutical, biotechnology, medical technology and healthcare service sectors. It provides financing in the form of equity, debt and non-dilutive financing for for buyout, growth, royalty acquisitions, structured transactions and hybrid financings. It acquires controlling stake in the company. | Finance |
AffaMed Therapeutics (HK) Ltd.
AffaMed Therapeutics (HK) Ltd. BiotechnologyHealth Technology Develops and commercializes ophthalmology, neurological and psychiatric products | Health Technology |
Davita, Inc. (Singapore) |
